|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||231.06 / 234.93|
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
These two firms have successful drugs and could make nice additions for larger companies.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
I still believe it will be a big year for buyouts across the biotech industry.
These high risk/high reward oncology names look significantly undervalued, right now.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.
This is the kind of reversal that happens in a bull market.
Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
These names are moving up or down in a big way ahead of releasing drug-trial results.
American Society of Clinical Oncology will see presentations from dozens of companies.
When there is no real worry, stocks can keep on running, but the rampage in the Nasdaq 100 is not unlike frothy action of the past.